- Home
- ALZN vs YCBD Comparison
ALZN vs YCBD Comparison
Compare ALZN & YCBD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALZN
- YCBD
- Stock Information
- Founded
- ALZN 2016
- YCBD 2015
- Country
- ALZN United States
- YCBD United States
- Employees
- ALZN N/A
- YCBD N/A
- Industry
- ALZN Medicinal Chemicals and Botanical Products
- YCBD Biotechnology: Pharmaceutical Preparations
- Sector
- ALZN Health Care
- YCBD Health Care
- Exchange
- ALZN Nasdaq
- YCBD Nasdaq
- Market Cap
- ALZN 8.2M
- YCBD 7.8M
- IPO Year
- ALZN 2021
- YCBD N/A
- Fundamental
- Price
- ALZN $2.50
- YCBD $0.69
- Analyst Decision
- ALZN Strong Buy
- YCBD Strong Buy
- Analyst Count
- ALZN 1
- YCBD 1
- Target Price
- ALZN $45.00
- YCBD $2.00
- AVG Volume (30 Days)
- ALZN 88.6K
- YCBD 98.5K
- Earning Date
- ALZN 09-10-2025
- YCBD 08-14-2025
- Dividend Yield
- ALZN N/A
- YCBD N/A
- EPS Growth
- ALZN N/A
- YCBD N/A
- EPS
- ALZN N/A
- YCBD N/A
- Revenue
- ALZN N/A
- YCBD $19,026,064.00
- Revenue This Year
- ALZN N/A
- YCBD $0.37
- Revenue Next Year
- ALZN N/A
- YCBD $4.95
- P/E Ratio
- ALZN N/A
- YCBD N/A
- Revenue Growth
- ALZN N/A
- YCBD N/A
- 52 Week Low
- ALZN $2.06
- YCBD $0.59
- 52 Week High
- ALZN $17.10
- YCBD $6.54
- Technical
- Relative Strength Index (RSI)
- ALZN 52.23
- YCBD 43.27
- Support Level
- ALZN $2.33
- YCBD $0.68
- Resistance Level
- ALZN $2.64
- YCBD $0.75
- Average True Range (ATR)
- ALZN 0.13
- YCBD 0.05
- MACD
- ALZN 0.04
- YCBD 0.00
- Stochastic Oscillator
- ALZN 66.10
- YCBD 16.54
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
About YCBD cbdMD Inc.
cbdMD Inc is a United States based company. It owns and operates the consumer hemp-based cannabidiol (CBD) brand, cbdMD, Paw CBD as well as ATRx Labs brand of functional mushrooms. The company's product categories include CBD tinctures, CBD gummies, CBD topicals, CBD capsules, CBD oils, and CBD pet products. The firm distributes its products through an e-commerce website, wholesalers, and a variety of brick-and-mortar retailers.